CytoMed Therapeutics Ltd Dossier
Qualitative Analysis
Business overview
CytoMed Therapeutics Limited (NASDAQ: GDTC) is a Singapore-based, clinical-stage biopharmaceutical company incorporated in 2018. The company is dedicated to developing novel, affordable, donor-derived (allogeneic) cell-based immunotherapies for treating a broad range of human cancers, including both hematological malignancies and solid tumors. CytoMed's proprietary technology platforms leverage gamma delta (ΓΔ) T cells and induced pluripotent stem cell (iPSC)-derived gamma delta Natural Killer T (gdNKT) cells. Its lead product candidate, CTM-N2D, consists of expanded ΓΔ T cells grafted with natural killer group 2D (NKG2D) ligands-targeting chimeric antigen receptors, currently undergoing Phase I clinical trials in Singapore. By utilizing healthy donor-derived cells, CytoMed aims to bypass the high costs, manufacturing complexities, and graft-versus-host disease (GvHD) risks associated with traditional autologous CAR-T therapies.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Establishing a multi-site, first-in-human Phase I clinical trial in Malaysia in collaboration with Universiti Malaya to investigate the safety and efficacy of patented allogeneic unmodified Gamma Delta (̴̴) T cells (CTM-GDT) for no-option cancer patients.
Expected impact: Expands clinical footprint into Malaysia, which is rapidly becoming an international medical tourism hub, and advances the unmodified gamma delta T cell platform.
Repurposing and enhancing the newly acquired TCB-002 allogeneic gamma delta T cell technology for cancer treatment in China and India. The strategy focuses on developing a non-cell-based manufacturing method using cytokines rather than living cells to bypass strict biological material import/export rules and align with China's State Council Decree No. 818.
Expected impact: Establishes a scalable, lower-cost beachhead in high-population markets (China and India) under favorable local regulatory pathways.
Diversifying into cord blood-derived natural killer (NK) cell therapies and personalized cellular banking services through the subsidiary LongevityBank. The long-term vision is to spin off LongevityBank as a standalone cord blood-based biopharmaceutical company focusing on autologous therapies.
Expected impact: Creates a distinct business line for autologous therapies and personalized cell banking, leveraging the company's licensed Malaysian cord blood bank assets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire the clinically validated TCB-002 technology, which previously completed a Phase I clinical trial in Europe and received FDA orphan drug designation for Acute Myeloid Leukemia. The acquisition strengthens CytoMed's expertise in allogeneic cell therapies and accelerates its commercialization timeline.
Financial impact: Funded through internal resources; not expected to have an immediate material financial impact on the company's operating results.
To secure a licensed cord blood bank in Malaysia (one of only three in the country), providing cryopreservation equipment, over 12,000 cord blood units, and two freehold real estate properties. This provides cost-free raw materials for strategic expansion into cord blood-derived therapeutics.
Financial impact: Funded through internal resources; provides long-term cost savings by securing proprietary raw materials.
Strategic Partnerships
Establishes a multi-site, first-in-human Phase I clinical trial in Malaysia to investigate the safety and efficacy of CytoMed's patented unmodified Gamma Delta T cells (CTM-GDT) for no-option cancer patients.
Terms: Undisclosed clinical collaboration terms.
Secured a non-dilutive investment of up to $500,000 for a 10% post-money stake in CytoMed's subsidiary, LongevityBank, to fund personalized cellular banking services and autologous therapy development.
Terms: Up to US$500,000 investment in exchange for a 10.0% post-money equity stake in LongevityBank Pte Ltd.